<DOC>
	<DOCNO>NCT01028404</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial investigate safety , tolerance , pharmacokinetics ( exposure drug ) pharmacodynamics ( effect ) NN1952 tablets healthy volunteer subject type 1 type 2 diabetes . The trial consist two part . In part 1 , single escalating dos NN1952 , placebo insulin aspart give healthy volunteer . In part 2 , subject type 1 type 2 diabetes receive single dos NN1952 ( with/without meal ) , insulin aspart placebo .</brief_summary>
	<brief_title>A Two Part Trial Investigating NN1952 Healthy Subjects Subjects With Type 1 Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<criteria>FOR TRIAL PART 1 , THE FOLLOWING APPLIES : Gender : male Age : 1855 year BMI ( body mass index ) : 1828 kg/m2 Study participant consider healthy FOR TRIAL PART 2 , THE FOLLOWING APPLIES : Gender : male female childbearing potential Age : 1865 year Type 1 diabetes : BMI ( body mass index ) : 1828 kg/m2 Type 2 diabetes : BMI ( body mass index ) : 2235 kg/m2 Type 1 type 2 diabetes least 12 month Type 1 diabetes : Treatment insulin least 12 month Type 2 diabetes : Treatment insulin least 3 month Known suspect allergy trial product relate product Presence illness infection may confound result study pose risk study participant dose NN1952 , judge Investigator Presence acute gastrointestinal symptom ( example nausea , vomit , heartburn diarrhoea )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>